STCube, Inc (052020) Fair Value & Analysis
Technology · KR · Market cap 768B KRW
Fair value as of: Jun 24, 2026
Analysis
STCube, Inc (052020) currently trades at 9,710 KRW, while our model-based Fair Value estimate is 4,105 KRW — implying the stock looks roughly 57.7% overvalued today. We read business quality at 95/100 (high quality), in the Technology sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).
About the company
STCube, Inc., a biopharmaceutical company, develops therapies to treat novel immune evasion mechanisms in cancer in South Korea. Its platforms include STGlyTarget that is used for the identification and development of immunomodulatory proteins; Immunomodulator Discovery Platform, a proprietary technology to screen for immunomodulatory proteins; Glyco-Specific Antibody Development Platform, a technology designed to screen for antibodies that selectively mask specific sites of target proteins; and Glyco-Specific Antibody Characterization and Optimization Platform, a technology designed to optimize characteristics exerted by antibodies that mask specific sites of target proteins. The company's product pipeline consists of various anti-cancer drugs, including programmed death ligand 1, a type of protein, which is expressed in cancer cells and interferes with the natural tumor killing of immune cells; programmed death-1, a type of protein that is expressed in T cells; and cytotoxic T-lym…
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is STCube, Inc (052020) undervalued?
What is the fair value of 052020?
What is the quality score of 052020?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.